Search research articles
Contact Us
Filters
Showing results (81-90 of 144) with videos related to
Page
of 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2013
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer
Gopa Iyer, Hikmat Al-Ahmadie, Nikolaus Schultz, et al.
The Journal of Urology
|
January 19, 2016
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma
Aditya Bagrodia, Eugene K Cha, John P Sfakianos, et al.
JCO Precision Oncology
|
March 12, 2019
Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome
Timothy F Donahue, Aditya Bagrodia, François Audenet, et al.
The New England Journal of Medicine
|
March 6, 2024
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Thomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Cancer
|
August 9, 2020
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma
Victor McPherson, Brendan Reardon, Aravind Bhayankara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2018
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Nature Medicine
|
February 27, 2026
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
Matthew D Galsky, Charlene Mantia, Michaela Bowden, et al.
Nature Communications
|
April 12, 2022
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
Jeppe Sejerø Holm, Samuel A Funt, Annie Borch, et al.
European Urology Oncology
|
December 17, 2023
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Pavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, et al.
Future Oncology (London, England)
|
January 31, 2025
A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study
Thomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 144) with videos related to
Sort By:
Page
of 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2013
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer
Gopa Iyer, Hikmat Al-Ahmadie, Nikolaus Schultz, et al.
The Journal of Urology
|
January 19, 2016
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma
Aditya Bagrodia, Eugene K Cha, John P Sfakianos, et al.
JCO Precision Oncology
|
March 12, 2019
Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome
Timothy F Donahue, Aditya Bagrodia, François Audenet, et al.
The New England Journal of Medicine
|
March 6, 2024
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Thomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Cancer
|
August 9, 2020
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma
Victor McPherson, Brendan Reardon, Aravind Bhayankara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2018
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Nature Medicine
|
February 27, 2026
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
Matthew D Galsky, Charlene Mantia, Michaela Bowden, et al.
Nature Communications
|
April 12, 2022
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
Jeppe Sejerø Holm, Samuel A Funt, Annie Borch, et al.
European Urology Oncology
|
December 17, 2023
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Pavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, et al.
Future Oncology (London, England)
|
January 31, 2025
A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study
Thomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Page
of 15